Last updated on May 2020

Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients

Brief description of study

The primary objective is to demonstrate the superiority of subcutaneous erenumab compared to oral prophylactic(s) on sustained benefit defined as % subjects completing one-year on the randomized treatment and achieving at least a 50% reduction from baseline in monthly migraine days at month 12.

Clinical Study Identifier: NCT03927144

Find a site near you

Start Over

DADO Medical S R O

Prague, Czechia
  Connect »

Clintrial SRO

Praha 10, Czechia
  Connect »

Thomayerova Nemocnice

Praha 4, Czechia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.